Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Achillion Pharmaceuticals Inc (NASDAQ:ACHN)

8.52
Delayed Data
As of Jul 31
 +0.13 / +1.55%
Today’s Change
6.76
Today|||52-Week Range
16.87
-30.45%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.0B

Company Description

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative treatments for infectious diseases. The company is currently engaged in the development of antivirals for the treatment of chronic hepatitis C infection and resistant bacterial infections. Its products include ACH-3102, ACH-2684, Sovaprevir and ACH-3422. Achillion Pharmaceuticals was founded on August 17, 1998 and is headquartered in New Haven, CT.

Contact Information

Achillion Pharmaceuticals, Inc.
300 George Street
New Haven Connecticut 06511
P:(203) 624-7000
Investor Relations:
(203) 752-5510

Employees

Shareholders

Other institutional57.40%
Individual stakeholders46.48%
Mutual fund holders40.14%

Top Executives

Milind S. DeshpandePresident, Chief Executive Officer & Director
Mary Kay FentonCFO, Secretary, EVP & Investor Relations Contact
David ApelianChief Medical Officer & Executive Vice President
Joseph TruittChief Commercial Officer & Executive VP
Glenn SchulmanHead-Investor Relations